Internal Reference Number: FOI_8228
Date Request Received: 23/10/2024 00:00:00
Date Request Replied To: 07/11/2024 00:00:00
This response was sent via: By Email
Request Summary: Chronic lymphocytic leukaemia (CLL)
Request Category: Companies
| Question Number 1: How many newly diagnosed patients with chronic lymphocytic leukaemia (CLL) have started first-line treatment in your Trust or Centre during the 6-month period February 2024 to July 2024? | |
| Answer To Question 1: 3 | |
| Question Number 2: How many of these newly diagnosed patients with CLL received chemoimmunotherapy (CIT) as first-line treatment? CITs include fludarabine + cyclophosphamide + rituximab (FCR), fludarabine + rituximab (FR), bendamustine + rituximab (BR), bendamustine monotherapy, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone (R-CHOP), obinutuzumab ± chlorambucil, rituximab + chlorambucil and ofatumumab | |
| Answer To Question 2: zero | |
| Question Number 3: Please see attached question and answer sheet. | |
| Answer To Question 3: Please see answer to Q3 attached. To accompany this answer to question 3 please also see the documents listed below:  FOI 8228 - Q3 - question and answer sheet (2).pdf | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
